Industry news
AstraZeneca rejects Pfizer final offer
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal comprising £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share (based on the closing price of Pfizer shares on 16 May 2014). This proposal undervalues the Company and its attractive prospects and has been rejected by the Board of AstraZeneca.